The release centered on three radiopharmaceutical programs and a set of updated clinical data points that showed how results have progressed over time.
The most advanced asset, [212Pb]VMT-α-NET, continued to build on earlier findings in neuroendocrine tumors. The company said the ongoing Phase 1/2a study had now treated 68 patients with follow-up data included in the analysis. It highlighted that responses deepen over time and that the treatment showed durable disease control across all doses. A key safety metric also remained in focus: blood creatinine during follow-up for all treated patients (n=68) was presented as part of the safety package. The company said the data supported moving toward a potential registration study at the current dose level.
For VMT01, the melanoma program, the update pointed to preliminary anti-tumor activity at the 3.0 mCi dose in the ongoing Phase 1/2a open-label trial. The release also referenced a table of treatment-emergent adverse events, with events reported at all grades and occurring in at least 10% of patients. The company said the early activity and tolerability profile supported further development.
The third program, PSV359, is being tested in advanced solid tumors. The release said the asset had shown improved tumor retention, which it framed as strengthening its potential as a therapeutic agent. No patient count or response rate was disclosed in the text provided, but the emphasis was on the change in retention performance versus earlier expectations.
Beyond the clinical readouts, the company stressed that its radiopharmaceutical platform is built around 212Pb and that it is advancing a wholly owned portfolio across multiple tumor types, including SSTR2-positive neuroendocrine tumors, melanoma, and FAP-alpha–expressing solid tumors. As a result of these announcements, the company's shares have moved -3.68% on the market, and are now trading at a price of $3.795. Check out the company's full 8-K submission here.
